

1
2
3
4 **“...but I know something’s not right here”:**

5 **Exploring the diagnosis and disclosure experiences of persons living with ALS**

6
7 Kathleen M. Foldvari¹

8 Paul Stolee^{1,2}

9 Elena Neiterman¹

10 Veronique Boscart¹

11 Catherine Tong¹

12
13 ¹ School of Public Health Sciences, University of Waterloo, Waterloo, Canada

14
15
16
17
18
19 ²Corresponding author

20 Address for Correspondence: Dr. Paul Stolee, School of Public Health Sciences, University of
21 Waterloo, Waterloo, Canada, N2L 3G1

22 E-mail: stolee@uwaterloo.ca

23 Abstract

24

25 **Background:** Amyotrophic Lateral Sclerosis (ALS), an incurable motor neuron disease,
26 primarily affects those between the ages of 60-79, and has an approximate post-diagnosis life--
27 expectancy of only two to five years. The condition has an unpredictable but ultimately terminal
28 trajectory that poses a number of challenges for patients, caregivers and healthcare providers.
29 While the diagnosis and disclosure are critical periods for intervention and support, knowledge
30 regarding the relational, communicational and psychodynamic forces that occur within the
31 process of diagnostic disclosure is relatively limited.

32 **Objectives:** The purpose of this study was to explore the experiences of persons living with
33 ALS in the diagnosis and disclosure of the condition, and the experiences of their caregivers.

34 **Methods:** We conducted a focus group and in-depth individual interviews with Canadians living with
35 ALS (n = 9), family caregivers (n = 7), a professional caregiver (n = 1), and one past caregiver (1). The
36 interviews were transcribed, cleaned, and anonymized, and then entered into NVivo 11 for thematic
37 analysis.

38 **Results:** Participants discussed the diagnosis process, including the inklings and subtle changes
39 prior to diagnosis, attempts at self-diagnosis, and the lengthy assessment process. Time was also
40 a consideration in the disclosure process, in which participants shared how the diagnosis
41 disclosure was the product of longstanding conversations with their care providers. It was
42 described as rarely a shock to finally have confirmation. Additionally, participants shared their
43 information seeking strategies and needs for a diagnosis that, for them, typically came with
44 insufficient information on the disease, prognosis, and next steps.

45 **Significance:** This project serves as an initial step in bridging the relevant gaps in our knowledge
46 and understanding towards improved patient-centered care practices in the diagnosis and
47 disclosure of ALS.

48

49

50 **Keywords:** Amyotrophic Lateral Sclerosis (ALS), Diagnostic Disclosure, Qualitative methods,
51 Caregivers

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

Introduction

84

ALS is a progressive and incurable multi-system disorder characterized by muscle

85

wasting, severe disability, and unpredictable illness trajectories. Its symptoms are caused by

86

rapid brain and spinal cord nerve cell degeneration, and typically lead to death within three

87

years of initial symptom onset [1-3]. ALS is a burdensome and typically terminal disease that

88

causes great stress and uncertainty for the individual with the disease, and all those in their circle

89

of care [4-6].

90

At present, there are approximately 200,000 people globally who are living with ALS

91

[7], and it is predicted that the global incidence of ALS will increase nearly 70% by the year

92

2040 [8]. This anticipated increase in diagnosed cases of ALS has been attributed, largely, to the

93

aging of the population. The number of older adults, worldwide, is expected to reach two billion

94

by 2050 [9]; ALS is classified as an “age-dependent neurodegenerative disease” [10]. The ALS

95

rate of incidence peaks around the eighth decade of life, while the majority of those living with

96

the condition are between the ages of 60-79 years [8,10-12].

97

A lack of familiarity with the unique nature of ALS limits healthcare providers in being

98

able to answer patients’ questions and direct their care appropriately. This lack of knowledge

99

about the condition has the potential to create gaps in the continuity of care starting with

100

diagnosis [2,13-15]. ALS’ relentless attack on the body’s physical functioning, as well as its

101

incurable nature, make the disease an unfavorable diagnosis. People are reported to respond to

102

hearing a diagnosis of ALS with a range of emotions. It is not unusual for patients to experience

103

initial shock and distress, anger or worry [16-19]. As is true for many people faced with bad

104

news about their health, it is common for people to struggle emotionally. Experiences with

105

denial or wishful thinking throughout the disease course are also common reactions that are

106 recognized in the literature [20-23]. Some studies suggest that more attention ought to be paid to
107 patients' emotional coping needs, as their emotional coping can have a significant impact on
108 how they are able to engage in health planning related to their overall health outcomes
109 [16,18,21,24,25]. In response to such evidence, general guidelines for diagnostic disclosure have
110 been developed and implemented to help healthcare providers effectively deliver bad news to
111 their patients, while identifying and dealing with unfavoured coping mechanisms such as denial,
112 e.g., [14,17,18]. Though well received, many of the current guidelines were not developed or
113 tested specifically for use in ALS care. When it comes to communication and relational care,
114 current practices in ALS care are, and have typically been, guided by parameters outlined for
115 cancer care focused initiatives [20,26-28].

116 **The diagnosis of ALS**

117 Diagnosing ALS is typically a very involved process, as there is no one test that can
118 determine, with certainty, whether or not the presented symptoms are related to the disease
119 [2,13,19]. The *El Escorial* criteria for the diagnosis of ALS, originally developed in 1990 by the
120 World Federation of Neurology and updated in 2000, are applied worldwide by clinicians and
121 scientists in efforts to identify and classify symptoms of the disease as they are related to either
122 upper or lower motor neuron degeneration [29].

123 In Canada, primary care physicians are usually a patient's first point of contact with the
124 healthcare system [30]. For ALS patients, and those presenting with possible symptoms of the
125 condition, primary care services offer referral and access to multidisciplinary care clinic teams
126 that ideally work in a coordinated way to facilitate the diagnostic process, help guide efforts in

127 symptom management, and support the prevention of medical complications and premature
128 death [24,30-32].

129 A patient’s journey often begins with complaints of preliminary symptoms such as:
130 muscle cramps, weakness and fatigue. Shortness of breath, numbness, and/or tingling in the
131 extremities are also common first symptoms. After noticing these first symptoms, patients will
132 seek out a primary care physician to help make sense of their symptoms and consider their case..
133 The primary care physician will then make a referral to a specialized neurologist for testing and
134 disease confirmation, if appropriate. Once ALS has been confirmed through the reasonable
135 exclusion of other conditions, the patient’s specific needs are assessed and a care team is
136 assembled [1,24,31,32].

137 A confirmed diagnosis is often a prerequisite to gaining access to specialized and
138 funded services, such as specialized ALS clinics. A confirmed diagnosis can take upwards of a
139 year, and misdiagnosis is relatively common in the initial stages of the process [1,2,13]. The
140 often-convoluted process of arriving at a confirmed diagnosis of ALS can often affect patients’
141 relationships with their care providers, and thus their overall satisfaction with their care,
142 making good communication an essential part of the process [1,33,34].

143 **The diagnosis disclosure of ALS, a critical period for intervention**

144 While a diagnosis is defined as the “the art or act of identifying a disease from its signs
145 and symptoms” [35], diagnostic disclosure specifically refers to the act of sharing the diagnosis
146 with the patient and/or caregivers. Diagnostic disclosure is a term typically used when a clinician
147 is disclosing diagnoses with serious and long-term implications, such as dementia or autism [36].
148 Most tools and guidelines currently available for diagnostic disclosure do not offer specific

149 instructions for how to go about disclosing the diagnosis of ALS towards successful coping
150 [24,26,37], although Pizzimenti and colleagues [18] do offer some guidance on the timing,
151 location and communication of the diagnosis. Despite some existing guidance, a large number of
152 physicians report experiencing a great deal of stress and uneasiness when breaking the news of
153 terminal illness to patients. Meanwhile, many patients say that they are left feeling under-
154 informed and dissatisfied after hearing the news [38-40]. There is still a need for practice-level
155 improvements to be made to the disclosure process for ALS [38,41].

156 As a sensitive and stressful step in the care process, diagnostic disclosure is a critical
157 period for intervention which is potentially predictive of future coping-related outcomes
158 [40,42,43]. There is likely to be great benefit in working towards improving current guidelines
159 and recommendations by expanding our knowledge base about peoples' experiences in the
160 process.

161 **Past & present approaches to diagnostic disclosure**

162 Two commonly used tools for the diagnostic disclosure of serious conditions include the
163 six-step SPIKES protocol, described by Baile et al. [20], and the parameters outlined by
164 Andersen et al. [24] of the European Federation of the Neurological Societies (EFNS) task force.
165 The SPIKES protocol lays out a series of steps to be followed during conversations in which bad
166 news is delivered. These steps are aimed at guiding healthcare providers in gathering
167 information, transmitting relevant information, providing support, and encouraging patients'
168 engagement in care planning [20]. The EFNS task force lists a number of recommendations to be
169 considered prior to and during conversations in which a diagnosis of ALS is to be relayed.
170 Among the recommendations listed are: a comfortable quiet setting in which to communicate the

171 bad news; an understanding of who the patient is, and what their communicational preferences
172 are, prior to disclosure; and the use of simple and carefully worded statements [24]. This is not
173 dissimilar to the recommendations made by Pizzimenti et al. [18], specific to the disclosure of
174 ALS.

175 Both tools (SPIKES and EFNS) have been correlated with improvements in patients’
176 satisfaction surrounding the manner in which the news of their illness was broken to them [38-
177 40]. However, many physicians still report experiencing a great deal of stress and uneasiness
178 when breaking the news of terminal illness to patients, while patients are left with many
179 questions about their condition [38,41,44,45]. This literature suggests that parameters for
180 diagnostic disclosure tend to be vague and do not meet expectations for supporting healthcare
181 providers in facilitating conversations that focus on outcomes, rather than just treatment options,
182 with their patients. This creates a risk for negative experiences in both care provision and on the
183 receiving end [24,38,44,46,47].

184
185 A deeper understanding of varying ALS care experiences could lay the foundation for
186 improving the diagnostic and disclosure process, potentially leading to improved coping and
187 quality-of-life [18,38,40,41,43]. The current study seeks to understand the experiences of
188 diagnosis and disclosure of persons living with ALS, with the support from their caregivers.

189 **Materials and Methods**

190 We utilized a qualitative interview approach to capture participants’ experiences in
191 diagnosis and disclosure of ALS [48-50]. Data collection took place in Southern Ontario,
192 Canada, from October 2017 to June 2018.

193 **Eligibility & recruitment**

194 Patients diagnosed with the various ALS types, as well as caregivers, were eligible. No
195 participants were excluded based on their gender, socio-economic status, race, ethnicity or
196 religious affiliation. Though the median age for ALS symptom onset is about 62 years of age,
197 most people who develop ALS are between 40 and 70 years [8,12,51]. This study thus sought to
198 collect data from and about adults (both male and female) roughly within the indicated age range
199 and beyond; this study was not restricted to patients living with ALS at ages conventionally
200 defined as “older” (i.e., 65+). The eligibility of caregivers to participate in the study was based
201 on self-report of their involvement in the care of someone diagnosed with ALS, whether they
202 were a partner, family member, or friend.

203 This study received ethics clearance from the University of Waterloo Office of Research
204 Ethics [ORE # 22512]. In the role of a gatekeeper [52], the ALS Society of Canada shared our
205 recruitment materials (emails and recruitment posters) with potentially eligible individuals.

206 **Data collection**

207 In October 2017, a group of three patients living with ALS and six caregivers
208 participated in an audio-recorded focus group interview in which participants discussed their
209 experiences with diagnosis and disclosure. The focus group participants also helped develop the
210 interview guides for subsequent individual interviews; these included one interview guide for
211 use with patients and a second for use with caregivers.

212 In the Spring of 2018, thirteen participants were recruited to participate in semi-
213 structured interviews [48]; this included four individuals who had also participated in the initial
214 focus group. Between the focus group and individual interviews, a total of 18 unique individuals
215 participated in this study. Interviews took place at the time and location of the participants’

216 choosing and were conducted over the telephone or in-person. Individual and dyad interviews
217 were conducted based on the indicated preferences of the participants. Upon receipt of written
218 informed consent, interviews were audio-recorded, and later were manually transcribed verbatim
219 by the lead author. In the interviews, participants discussed their diagnosis and diagnostic
220 disclosure experiences and provided demographic information. The lead author also composed
221 field notes throughout the data collection period (October 16, 2017 to June 20, 2018). This study
222 was limited in time and scope, and saturation or “data adequacy” [53] may not have been
223 achieved.

224 **Description of sample**

225 The average age of participants with ALS was 55 years, ranging between approximately
226 30 to 70 years (rounded for anonymity). The average age of all caregiver participants was 44
227 years, ranging between approximately 25 and 60 years (rounded for anonymity). The average
228 age of caregivers, as stated, represents all types of caregiver participants in the sample excepting
229 one family caregiver who declined to complete the demographics form. All participants lived in
230 southern Ontario, except one who lived in British Columbia and completed their interview
231 remotely.

232 The majority of the participants with ALS or similar diagnosis were male, while the
233 majority of the caregiver participants (including past and professional) identified as female.
234 Participants reported diagnoses of various types and motor neuron disease (MND) sub-types
235 including probable/ atypical ALS, confirmed ALS, confirmed PLS (one person with Partial
236 Lateral Sclerosis (PLS), a motor neuron disease similar to ALS, participated in the focus group
237 interview), confirmed ALS – slow progressing, with some overlap between categories, where

238 participants were given more than one related diagnosis. The overlap is attributed to initial
 239 misdiagnoses and/or multiple opinions from different healthcare providers. Participants spoke to
 240 their unique experiences identifying with the ALS diagnosis and its sub-types as they received
 241 opinions from various healthcare providers. These diagnoses were reported to have occurred
 242 between the years of 2010 to 2017. All participants described a path to diagnosis that began with
 243 either a visit to a family doctor or walk-in clinic physician upon symptom onset, followed by a
 244 referral to an ALS clinic for specialized diagnostics and care Final ALS diagnoses were made by
 245 specialized neurologists. See Tables 1 and 2 for participants’ summaries; summaries edited for
 246 confidentiality.

247 **Table 1. Participant Sample Summary (Focus Group Interview), n=9**

Gender	Role/ Relationship	~Age	Loc ale	Interview Format	Approximate Date/ Nature of Diagnosis
F	Caregiver – Professional	40	Large Urban City (Greater Toronto Area), ON	Group	
F	Past Caregiver – Daughter	45	Small Town (Waterloo Region), ON	Group	
F	Person living with PLS	65	Small Town (Waterloo Region), ON	Group	2017 – Confirmed/ PLS
F	Caregiver – Daughter	35	Small Town (Waterloo Region), ON	Group	
F	Caregiver – Sister	Declined to answer	Declined to answer	Group	
F	Person living with ALS	45	Medium City (London Metro Area), ON	Group	September 2015 – Confirmed/ Slow progressing
M	Caregiver – Boyfriend	45	Large Urban City (Greater Toronto	Group	

			Area), ON		
M	Person living with ALS	55	Large Urban City (Kitchener Metro Area), ON	Group	Spring 2016 – Confirmed/ Progressed ALS
F	Caregiver – Cousin	50	Large Urban City (Kitchener Metro Area), ON	Group	

248

249 **Table 2. Participant Sample Summary (Individual and Dyad Interviews), n=13**

Gender	Role/ Relationship	~Age	Locale	Interview Format	Approximate Date/ Nature of Diagnosis
M	Person living with ALS	65	Large Urban City (Kitchener Metro Area), ON	Individual	October 2016 – Probable/ Atypical
M	Person living with ALS	30	Large Urban City (Greater Vancouver Area), BC	Individual	May 2016 – Confirmed/ Limb onset
F	Person living with ALS	55	Large Urban City (Kitchener Metro Area), ON	Dyad	2015/2016 – Confirmed
M	Caregiver – Son	25	Large Urban City (Kitchener Metro Area), ON	Dyad	
M	Person living with ALS	60	Large Urban City (Greater Toronto Area), ON	Individual	2015 – Confirmed/ Atypical; Lower MND Variant
M	Person living with ALS	50	Large Urban City (Kitchener Metro Area), ON	Dyad	Spring 2010 – Confirmed/ Slow progressing
F	Caregiver – Wife	50	Large Urban City (Kitchener Metro Area), ON	Dyad	
F	Caregiver – Wife	60	Large Urban City (Kitchener Metro Area), ON	Individual	
F	Person living with ALS	70	Large Urban City (Kitchener Metro Area), ON	Individual	2010 – Confirmed/ Slow progressing

F	Person living with ALS	45	Medium City (London Metro Area), ON	Dyad	September 2015 – Confirmed/ Slow progressing
M	Caregiver – Boyfriend	45	Large Urban City (Greater Toronto Area), ON	Dyad	
M	Person living with ALS	55	Large Urban City (Kitchener Metro Area), ON	Dyad	Spring 2016 – Confirmed/ Progressed ALS
F	Caregiver – Cousin	55	Large Urban City (Kitchener Metro Area), ON	Dyad	

250

251 **Analysis**

252 Data were cleaned, anonymized, and then uploaded to NVivo 11 for analysis. A
253 thematic analysis, as outlined by Braun & Clarke [54] was used. The thematic analysis
254 conducted for the purposes of this project aimed to understand the experiences of persons with
255 ALS through the eyes of patients and their caregivers and took place under epistemological
256 assumptions aligned with the constructionist paradigm. Under this system of belief, themes
257 were generated through an analysis of participant-described events and incidents, with the
258 understanding that people build their own realities as they navigate through, and create
259 meaning from, the world around them. The constructionist paradigm recognizes and embraces
260 the complexity of human life, which provided a suitable basis for understanding people in their
261 attempt to cope with a terminal illness: ‘what they do’ and ‘how they do it’ [54,55]. The data
262 analysis process occurred inductively, meaning that the researcher did not attempt to fit the data
263 into an existing framework or hypothesis, but rather let the data ‘tell the story’ [54].

264 Our analysis process included the lead author reading the transcripts twice, specifically
265 looking for patterns in the second reading; identifying codes that represented the data, and then
266 using printed copies of the codes to visually organize the codes thematically; defining each

267 code, and sharing these code definitions with co-authors for review; additional readings of the
268 transcripts and line-by-line coding in NVivo 11, and then isolating the most significant themes.
269 These themes were then shared with the study participants. All participants were presented with
270 summaries of the themes and asked to confirm or refute the findings.

271 **Strategies for rigor**

272 Strategies for rigor [56] included member checking to verify research findings, research team
273 debriefing, triangulating data and themes from different participant groups (e.g., caregivers and persons
274 living with ALS), and keeping detailed field notes during data collection. Regular notetaking was used
275 by the lead author to reflect on her perceptions, preconceptions, beliefs and values, and to attempt to
276 separate her personal experiences with ALS from those of the participants.

277

278 **Results**

279 Findings are clustered into two overarching themes, the first on participants' path to diagnosis,
280 and the second on participants' diagnosis disclosure experience, and accompanying needs. In both
281 themes, time and lengthy intervals were noted.

282 **The path to diagnosis: inklings and assessments**

283 Participants disclosed that their path through diagnosis was initiated by changes in
284 functional capacity or unusual sensations. For example, one participant with ALS said:

285

286 “Before [I was diagnosed] it was about my blood sugar...The family doctor...was
287 sending me for measurements of my blood sugar...one day...I was trying to do

288 push-ups...and I couldn't do it. I couldn't do it anymore...so, that was when I
289 went to [my family doctor]..." — [Person living with ALSI-1]

290
291 Participants described a series of events triggered by their initial symptoms that
292 involved a visit to either their family doctor or a doctor at a walk-in clinic. It was indicated
293 that this visit instigated initial tests ordered by the doctor, and processes of theory generating
294 and self- diagnosis. These processes are reflected in the following statement made by a
295 participant with ALS:

296
297 "...I started to feel like I was being electrocuted in my feet and legs... it just went
298 from my toes to my knees. And then as time continued to pass...[it was] moving
299 up my body... I pushed the doctor... to give me a possibility of what it could be
300 because I was getting a little bit frustrated. And...my wife and I had been reading
301 tens of dozens of articles on the Internet; and gone back and forth to each other
302 trying to cross-reference my symptoms...we came up with all sorts of things..."

303 — [Person living with ALSI-5]

304
305 Both patients and doctors seemed to have been speculating as to what might be
306 causing the symptoms, as illustrated by the statement above, as well as the following remarks
307 made by a person living with ALS and a caregiver, respectively:

308
309 "I was a...typical, healthy guy and noticed some atrophy in my left hand.
310 Specifically in the muscles that control the thumb...I was a cliché quote, unquote,
311 muscly kind of dude...I assumed that I pinched a nerve in my arm while
312 exercising or something like that..." — [Person living with ALSI-2]

313 "... initially, the degree of weakness was so mild...that's why I thought that it would be
314 something else...in terms of...weight loss...they were just thinking his nutritional status was
315 not very good...[that] he wasn't getting enough protein...Then they [thought]...maybe other
316 conditions also cause weight loss symptoms..."— [CAR1-8]

317

318 The conversations surrounding the first symptoms presented to participants' primary
319 care physicians (or first points of contact) involved a lot of back and forth in testing, and
320 referral to various specialists, otherwise characterized as a lengthy process of trial and error.
321 As one participant with ALS indicated: "...it was a bit of a revolving door...of characters
322 who sort of confirmed my diagnosis...people in and out..." [Person living with ALSI-2]. In
323 some cases, misdiagnosis and ineffective surgery or treatment aimed at symptom
324 management were also experienced. One participant with ALS said: "[It was] all just sort of
325 symptom management while we were trying to figure out what the problem was and once
326 targeted we could treat it...hopefully" [Person living with ALSI-5].

327 Others stated:

328 "...my hands started getting weak. I could barely turn the keys to unlock my car.
329 So, I went to the doctor and they said, something's not right... And then...[the
330 doctor] said: "I think you have carpal tunnel". So they did the surgery on both
331 hands and that didn't really help...Then that doctor said it must be something
332 different..." — [Person living with ALSI-9]

333 "I was a PSW [personal support worker] and I fell in the bathtub...it was drop
334 foot...and I knew something wasn't right...When I fell in that bathtub, I was fine. I
335 could run and jump until I fell in that bathtub...I kept working...and then I went to
336 [the doctor]...and I was getting acupuncture. For many years I kept going and
337 trying different things all the time..." — [Person living with ALSI-3]

339 The initial back and forth was ultimately followed by a determination, through a
340 process of elimination, that the presented symptoms were most likely neurological in nature.
341 This is said to have prompted final referrals made either to first, a local neurology specialist,
342 or directly to a major city clinic neurologist for similar assessments and observations of
343 symptom progression. One participant with ALS asserted: "...*basically they rule everything*
344 *out, and then as you continue to get worse, they say: "Hey, you got ALS"*" [Person living
345 with ALSI-2]. Two other participants explain similar experiences:

346

347 “...it's not an obvious thing, like you're going to break a leg, where you go into
348 any ER and they put a cast on you, and you're out the door type of thing. When it
349 is a diagnosis of exclusion and you don't know what it is...you got to figure out
350 what it is or what it isn't” — [Person living with ALSI-5]

351
352 “...they try to rule out everything else. Then they say you probably have ALS.
353 But, [they] refer [me] to a team in [a major city]...and they basically did the same
354 tests, and said the same thing: that I probably have ALS. Then they said about
355 nine months later they would follow-up...and then they said: “okay, you have
356 ALS”. — [Person living with ALSD-6]

357

358 This led some directly to acceptance, while others sought a second opinion first:

359

360 “...I went to [the clinic]...I [told] them, I don't know what I have. I don't know
361 if I have ALS or what I have. So, I asked for a second opinion and they said I had
362 a neurological disease. So I said, I don't know what I have, but I know
363 something's not right here” — [Person living with ALSD-3]

364

365 Overall, the process of diagnosis was described by participants as one characterized by
366 a great deal of back and forth, frustration, and hopeful theorizing. Participants indicated
367 putting a great deal of effort into ascertaining a label that best suited the symptoms that they
368 were experiencing.

369

370 **The diagnostic disclosure process: intervals and information**

371

372 For the participants in this study, all conversations surrounding diagnosis and
373 prognosis were conducted in-person, regardless of the healthcare provider that was relaying
374 the information. These conversations were indicated to have typically gone on for nine

375 months to about a year. In two cases, a confirmed diagnosis was reached after two to three
376 years:

377

378 “...there was maybe a year...maybe nine months of activity before [I received a
379 confirmed diagnosis]...but that’s the day essentially, that they exhausted all of
380 treatments and were monitoring my progression. Then they essentially concluded
381 and voiced to me that I had ALS” — [Person living with ALSI-2]

382 “I think it wasn't until [three years later] that we were really told: “Okay, at this
383 point between three different hospitals, we have run every conceivable test...and
384 in the absence of finding anything else that we could pin this on we have to
385 conclude that you have lower motor neuron onset ALS”” — [Person living with
386 ALSI-5]

387

388 On the other hand, a confirmed diagnosis was reached after a matter of weeks for
389 another case.

390 The process of receiving a confirmed diagnosis was described as not coming as a
391 surprise, but as confirming the suspected, based on the patients’ own research. This is
392 reflected in these quotes from persons living with ALS:

393

394 “...and between the first neurologist and the second I had done a lot of
395 research, so I had already decided that’s what I had. So, it wasn’t a surprise”
396 [Person living with ALSI-5].

397

398 “I was hoping for good news, but at the same time I wasn't completely
399 surprised about the bad news...given the independent study I did...I've
400 always had terrible luck. So right off the bat and given me reading the
401 Wikipedia page and noticing the physical symptoms I sort of concluded
402 independently...and with my pessimism...that I had ALS. But yeah, I was
403 noticing continued muscle atrophy, continued weakness, gradual, but obvious,
404 over those nine months. And when I finally got the word what it was, it was
405 one of these things that I had been expecting to hear I think” — [Person living
406 with ALSI-2]

407

408 After receiving a confirmed diagnosis, participants described a subsequent process of

409 convening a multidisciplinary care team. For example, one person living with ALS says:

410 “...once I got a confirmed diagnosis from the specialized ALS clinic, it’s been a whole care

411 team of a half dozen individuals that I see quite regularly” [Person living with ALSI-2].

412 Participants perceived their concrete diagnosis as pivotal, such that it sparked a will to push

413 forward and reassess personal priorities, such as for this participant who declared: “I can’t go

414 anywhere...I have too much to live for!” [Person living with ALSD-3].

415 Similarly, this person living with ALS shared:

416

417 “So essentially what happened...from that day forward it's like: okay, well, you

418 have three to five years or whatever math they give you....and pardon my

419 language, but it's like: fuck that! I’m not going in the office anymore. You know

420 what I mean? Like what's in it for me?” — [Person living with ALSI-2]

421

422 In trying to digest the diagnostic and prognostic information that was presented to

423 them, participants said that they took it upon themselves to educate themselves about their

424 condition:

425

426 “So I told [my wife] that night when I got home from work. And...when we went

427 to bed, we started looking it up on the Internet. And that’s how we realized that’s

428 all we had for those six weeks [until our next appointment]” — [Person living

429 with ALSD-6]

430

431 Participants criticized the healthcare system for long waits between appointment times

432 and complained that one of their most significant struggles in the diagnostic disclosure

433 process was the limited amount of information provided about the condition they were just

434 diagnosed with. One person living with ALS stated: “...*I knew what I had when I went to the*
435 *first neurologist...when she told me I probably have ALS. But, I didn't even know what that*
436 *was, and she wouldn't tell me*” [Person living with ALSD-6]. In this case, the participant
437 expected to receive information and education about their condition from their neurologist.
438 Instead, the neurologist gave the person pamphlets and told the person to “go home and look
439 it up on the Internet”. Their caregiver added: “...*when you first read [the pamphlets they give*
440 *you]...it's sickening. You just read what it is...you don't know. Just to be thrown [the*
441 *information], with no lead up to it is awful*” [CARD-7]. This scenario highlights the lack of
442 familiarity and discomfort with ALS diagnosis disclosure and its direct impact on patient
443 care.

444 Participants discussed that having a concrete diagnosis was helpful, in that it granted
445 them access to support from social organizations such as local ALS Society of Canada
446 chapters and home and community care services, and eligibility to participate in treatment
447 trials and clinical studies:

448
449 “I am going to be trying that new medicine...hopefully in the next few
450 weeks...[through the ALS clinic]...So I was waiting for the phone call
451 today...[from the ALS clinic neurologist]...” — [Person living with ALSD-3]

452 “...we filled out a million forms...So I'm now on the wait list for an interview
453 for...direct funding. And I now have...through [the local health authority], doing
454 personal support hours one hour daily. Which basically is: come in make me a
455 coffee, shower me...Cool. I'm hooked up with [the local hospice], but I haven't
456 heard back from them yet...” — [Person living with ALSD-10]

457
458 Generally, experiences of diagnostic disclosure were described as not a
459 surprise or a shock. Participants described having been grateful to be through the

460 diagnosis process, such that they were then able to begin to focus on establishing next
461 steps and understanding care and treatment options with a consistent care team.

462 **Discussion**

463 Current recommendations for diagnostic disclosure, as laid out by Baile et al. [20] and
464 Andersen et al. [24], advise verbal in-person sharing of diagnosis and prognostic information.
465 According to participants, this is indeed the way such conversations are typically carried out.
466 Participants did not share evidence to suggest that healthcare providers were implementing
467 recommendations such as offering an invitation to share information or exploring emotions as
468 in the SPIKES protocol and EFNS task force report [20,24]. However, the general process of
469 care as described in the literature was corroborated by the findings of this study. Persons with
470 ALS and caregivers in the current study explained that their journeys through the care system
471 began with the presentation of mild symptoms to a primary care physician, followed by a
472 diagnostic process of elimination, and a referral to a neurologist, a neurology specialist, or an
473 ALS clinic team in a major city. A formal diagnosis from a neurologist provided them access
474 to specific supports. This path is consistent with the descriptions of multiple sources both in
475 and outside of Canada [1,15,24,31,32]. Our findings are also consistent with the work of
476 Hogden et al. [16] who determined that the nature of the terminal prognosis associated with
477 ALS can make it difficult to manage dynamics in providing and receiving healthcare, as well
478 as patients' engagement in their care.

479 Most participants in our study were not surprised by their diagnosis at the point of
480 formal disclosure. Participants indicated that after having gone through a lengthy process of
481 trial and error, and having done their own theorizing and research throughout, receiving
482 confirmation of their diagnosis did not come as a shock, in contrast to the findings of some

483 prior studies. For example, Hogden et al. [16] reported that health professionals described
484 patients as being shocked by the diagnosis of ALS and as having difficulty accepting it. These
485 reactions were seen as delaying the provision of additional information and the
486 commencement of care planning. The same research group studied the perspectives of
487 patients' experiences of receiving an ALS diagnosis, again finding that shock was a common
488 reaction [57]. On the other hand, several patients in the latter study indicated that the
489 diagnosis was not a surprise, but a confirmation of their own conclusions [57], which was
490 consistent with experiences described by participants in our study.

491 Emotions of surprise and shock have been studied in the experiences of people
492 receiving a cancer diagnosis. Plage and Olsen [58] studied the illness narratives of people
493 living with cancer and found that surprise and shock (as an intense form of surprise) conveyed
494 the implication that the diagnosis of cancer for those expressing surprise was unexpected and
495 unpreventable and thus not the individuals' responsibility. In this study, the experience of
496 surprise, or the lack thereof, for persons living with ALS, reflected a different illness
497 experience. Persons living with ALS were not surprised by the diagnosis because they had
498 been led to that conclusion by a lengthy diagnostic process and their own information-
499 seeking, and not because they felt some sense of responsibility for having the condition (as
500 might be the case for a long-time smoker who is diagnosed with lung cancer).

501 Participants described the Internet as a significant tool in their quests to identify the
502 cause of their symptoms. Patients and caregivers talked about doing their own research using
503 the Internet as a tool. Participants explained that they brought the results of their searches and
504 discussions to their healthcare providers for further consideration and conversation. The
505 findings of Abdulla et al. [59] on information seeking behaviors on patients and their care
506 were similar to the findings of this study, in that patients and their caregivers sought

507 information from multiple sources, with many relying on Internet sources for information (as
508 was also found by [60]), and that they wanted to share and discuss the information they found
509 with their healthcare providers. Conducting their own independent research seemed to offer
510 participants in the current study a sense of control and authority during the diagnosis process.
511 This information seeking behavior may have contributed to their familiarity with their
512 condition, enough so to avoid surprise when they received their formal diagnosis.

513 Once they received confirmation of the suspected diagnosis, participants were finally
514 able to put a name to their condition and begin exploring their treatment options. In the case
515 of this sample, it was most common for participants to experience more of an intense reaction
516 to their initial symptoms, as they worried about their ability to continue to perform optimally
517 in life and at work. Participants began to reason and rationalize increasingly as they grew
518 more aware of the limited treatment options that existed for their condition; this was until they
519 slowly began to make peace with their circumstances, potentially facilitated by extended
520 rather than abrupt processes in diagnostic disclosure or confirmation.

521 Jakobsson Larsson and colleagues [14] found ALS patients to be less engaged in
522 information seeking, while continuous information seeking was quite common among persons
523 with ALS in this study. This may highlight a difference in coping needs for persons living in
524 community and patients in hospital, a setting in which knowledgeable healthcare providers
525 are typically more present and available. Participants described this as a means of informing
526 their own understanding of their condition in order to curb uncertainty, given the limited and
527 sometimes untimely information they received from healthcare providers. Participants
528 described information provision as generally lacking in their healthcare experience. However,
529 the sense of control and autonomy that they felt in doing their own research about their

530 condition is consistent with the empowerment to improve disease management and decision
531 making that Pizzimenti et al. [18], talk about fostering, using communication that considers
532 the information needs and goals of patients, as well as social, culture and other personal
533 factors. It also suggests that more formal direction on where and how to seek useful
534 information may help patients engage with the diagnosis process in a way that can reduce
535 prolonged processes in coming to a diagnosis by being referred to a specialist for symptoms
536 mistaken for other conditions [15,18]. Though concerns of overwhelming patients with too
537 much information, too soon, have been discussed by research groups such as McCluskey et al.
538 [38] and Connolly et al. [39], this present study suggest that persons with ALS want more
539 information about what to expect in their condition, and about available resources, than they
540 are currently receiving [61]. It is understandable that a long period of diagnostic uncertainty
541 along with worsening symptoms would motivate persons to seek information from the
542 Internet. The well-known concerns about the limited reliability of online health information
543 [59-61], which was acknowledged by some participants in this study, heighten the importance
544 of timely information from healthcare providers.

545 As indicated by both patients and caregivers, such information would facilitate coping
546 by providing people with a platform from which to create their own plans for proactive action
547 towards better management of their current and anticipated needs.

548 **Strengths and limitations**

549 This study used multiple types of data collection (a focus group interview, individual and
550 dyad interviews). The focus group interview allowed for an initial exploration of themes, and the
551 dyad and individual interview formats were principally driven by participant preference. Great care

552 was taken to center and focus on the voice of the person living with ALS. Across these different
553 types of data collection, the themes were largely consistent. Member checking with all participants
554 was used to further ensure their voices and experiences were appropriately captured in the analysis.

555 Limitations of this study include the limited reflection of the voices of older persons
556 living with ALS. Few persons with ALS over the age of 65 years participated in the study;
557 some potential participants over the age of 65 were too far progressed in their disease to
558 participate. This can be considered a limitation of the current study, as the experiences of
559 persons with ALS potentially with the highest needs were not captured. Future research
560 should give careful consideration to recruitment methods.

561 **Conclusion**

562 This project serves as an initial step in bridging the relevant gaps in our knowledge
563 and understanding toward improved patient-centered care practices in the diagnosis and
564 disclosure of ALS. This study has highlighted the importance of continuing, meaningful
565 communication between patients and healthcare providers to minimize uncertainty and to
566 support care planning. Further research will be necessary to corroborate and extend the study
567 results. It will be necessary to incorporate the voice of healthcare providers that play a role in
568 supporting people living with ALS and other closely related conditions, so that barriers and
569 resource limitations that they might face in trying to fulfill the needs and desires of their
570 patients can be identified. Religious-, cultural-, age-, and gender-specific needs will be
571 important areas of continued exploration. These current and future findings, together, could
572 support and improve the diagnosis and diagnosis disclosure experiences of persons living with
573 ALS, and their caregivers and providers.

574

575

576

577

Acknowledgements

578

The authors gratefully acknowledge the persons with lived experience of ALS who participated in the

579

interviews for this project, and the ALS Society of Canada for their assistance with recruitment. The

580

authors also thank Veronica Sacco and Christiano Choo for their help in reviewing and editing earlier

581

versions of this paper.

582

References

- 584 1. A Guide to ALS Patient Care for Primary Care Physicians. [Online].: ALS-Canada; 2016.
585 Available from: [https://als.ca/wp-content/uploads/2017/02/A-Guide-to-ALS-Patient-Care-For-](https://als.ca/wp-content/uploads/2017/02/A-Guide-to-ALS-Patient-Care-For-Primary-Care-Physicians-English.pdf)
586 [Primary-Care-Physicians-English.pdf](https://als.ca/wp-content/uploads/2017/02/A-Guide-to-ALS-Patient-Care-For-Primary-Care-Physicians-English.pdf).
- 587 2. Murray L, Butow PN. Advance care planning in motor neuron disease: A systematic review.
588 Palliative & supportive care. 2016; 14(4): 411-423.
- 589 3. Oliver D, Borasio GD, Johnston W. Palliative care in amyotrophic lateral sclerosis: From
590 diagnosis to bereavement. OUP Oxford. 2014.
- 591 4. de Wit J, Bakker LA, van Groenestijn AC, van den Berg LH, Schröder CD, Visser-Meily JM, et al.
592 Caregiver burden in amyotrophic lateral sclerosis: a systematic review. Palliative medicine. 2017;
593 32(1): 231-245.
- 594 5. Hecht MJLGE, Tigges S, Hillemacher T, Winterholler M, Hilz MJ, Heuss D, et al. Burden of care
595 in amyotrophic lateral sclerosis. Palliative Medicine. 2003; 17(4): 327-333.
- 596 6. Pagnini F, Rossi G, Lunetta C, Banfi P, Castelnuovo G, Corbo M, et al. Burden, depression, and
597 anxiety in caregivers of people with amyotrophic lateral sclerosis. Psychology, Health & Medicine.
598 2010; 15(6): 685-693.
- 599 7. ALS Canada. About ALS. [Online]. Available from: <https://als.ca/what-is-als/about-als/>.
- 600 8. Arthur KC, Calvo A, Price TR, Geiger JT, Chio A, Traynor BJ. Projected increased in
601 amyotrophic lateral sclerosis from 2015-2040. Nature Communications. 2016; 7: 12408.
- 602 9. World Health Organization. Ageing and health. [Online].; 2022. Available from:
603 [https://www.who.int/news-room/fact-sheets/detail/ageing-and-](https://www.who.int/news-room/fact-sheets/detail/ageing-and-health#:~:text=By%202050%2C%20the%20world%27s%20population,2050%20to%20reach%20426%20million.)
604 [health#:~:text=By%202050%2C%20the%20world%27s%20population,2050%20to%20reach%2042](https://www.who.int/news-room/fact-sheets/detail/ageing-and-health#:~:text=By%202050%2C%20the%20world%27s%20population,2050%20to%20reach%20426%20million.)
605 [6%20million.](https://www.who.int/news-room/fact-sheets/detail/ageing-and-health#:~:text=By%202050%2C%20the%20world%27s%20population,2050%20to%20reach%20426%20million.)
- 606 10. Wolfson C, Kilborn S, Oskoui M, Genge A. Incidence and prevalence of amyotrophic lateral
607 sclerosis in Canada: a systematic review of the literature. Neuroepidemiology. 2009; 33(2): 79-88.
- 608 11. Logroscino G, Tortelli R, Rizzo G, Marin B, Preux PM, Malaspina A. Amyotrophic lateral
609 sclerosis: An aging related disease. Current Geriatrics Reports. 2015; 4(2): 142-153.
- 610 12. Boyd JC, Cooper TA, O'Brian BD. The path to diagnosis for persons with ALS in Nova Scotia.
611 Dalhousie Medical Journal. 2016; 42(2): 3-6.
- 612 13. Jakobsson Larsson BJ, Nordin K, Nygren I. Coping with amyotrophic lateral sclerosis; from
613 diagnosis and during disease progression. J Neurol Sci. 2016; 361: 235-242.
- 614 14. Richards D, Morren J, Pioro E. Time to diagnose and factors affecting diagnostic delay in
615 amyotrophic lateral sclerosis. In: Araki T, ed. Amyotrophic Lateral Sclerosis. 2021 July 25;: 15-33.
- 616 15. Hogden A, Greenfield D, Nugus P, Kiernan MC. Engaging in patient decision-making in
617 multidisciplinary care for amyotrophic lateral sclerosis: the views of health professionals. Patient
618 Prefer Adherence. 2012a; 6: 691-701.
- 619 16. Pizzimenti A, Gori MC, Onesti E, John B, Inghilleri M. Communication of diagnosis in
620 amyotrophic lateral sclerosis: stratification of patients for estimation of individual needs. Frontiers in
621 psychology. 2015; 6: 745.

- 622 17. Hugel H, Grundy N, Rigby S, Young CA. How does current care practice influence the
623 experience of a new diagnosis of motor neuron disease? A qualitative study of current
624 guidelines-based practice. *Amyotrophic lateral sclerosis*. 2006; 7(3): 161-166.
- 625 18. Baile WF, Buckman R, Lenzi R, Glober G, Beale EA, Kudelka AP. SPIKES-A six-step protocol
626 for delivering bad news: application to the patient with cancer. *Oncologist*. 2000; 5(4): 302-311.
- 627 19. Williams AR, Olfson M, Galanter M. Assessing and improving clinical insight among patients
628 "in denial". *JAMA psychiatry*. 2015; 72(4): 303-304.
- 629 20. Chu HS, Oh J. Information needs and preferences of family caregivers of patients with
630 amyotrophic lateral sclerosis. *Journal of Neuroscience Nursing*. 2020; 52(5): 207-213.
- 631 21. Zimmermann C. Denial of impending death: A discourse analysis of the palliative care literature.
632 *Social Science & Medicine*. 2004; 59(8): 1769-1780.
- 633 22. EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis; Andersen
634 PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Damme PV, Hardiman O, Kollewe K,
635 Morrison EK, Petri S, Pradat P, Silani V, Tomik B, Wasner M, Weber M. EFNS guidelines on the
636 clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force.
637 *Eur J Neurol*. 2012;19(3):360-375. doi:10.1111/j.1468-1331.2011.03501.x
- 638 23. Brown J, Addington-Hall J. How people with motor neurone disease talk about living with their
639 illness. A narrative study. *Journal of Advanced Nursing*. 2008; 62(2): 200-208.
- 640 24. Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshe D, Johnston W. Practice parameter
641 update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom
642 management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality
643 Standards Subcommittee of the American. *Neurology*. 2009; 73(15): 1227-1233.
- 644 25. Bolmsjo I, Hermeren G. Interviews with patients, family, and caregivers in amyotrophic lateral
645 sclerosis: Comparing needs. *Journal of palliative care*. 2001; 17(4): 236.
- 646 26. Astrow AB, Sood JR, Nolan MT, Terry PB, Clawson L, Kub J, et al. Decision-making in patients
647 with advanced cancer compared with amyotrophic lateral sclerosis. *Journal of Medical Ethics*. 2008;
648 34(9): 664-668.
- 649 27. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the
650 diagnosis of amyotrophic lateral sclerosis. . *Amyotrophic lateral sclerosis and other motor neuron*
651 *disorders*. 2000; 1(5): 293-299.
- 652 28. Soriani MH, Desnuelle C. Care management in amyotrophic lateral sclerosis. *Revue*
653 *neurologique*. 2017; 173(5): 288-299.
- 654 29. Canadian Institute for Health Information. Primary Health Care in Canada: A Chartbook of
655 Selected Indicator Results. [Online].; 2016. Available from:
656 <https://secure.cihi.ca/estore/productFamily.htm?locale=en&pf=PFC3137>.
- 657 30. Mitsumoto H, G. RJ. Palliative care for patients with amyotrophic lateral sclerosis: "Prepare for
658 the worst and hope for the best". *JAMA*. 2007; 298(2): 207-216.
- 659 31. Hogden A, Foley G, Henderson RD, James N, Aoun SM. Amyotrophic lateral sclerosis:
660 Improving care with a multidisciplinary approach. *Journal of multidisciplinary healthcare*. 2017; 10:
661 205.
- 662 32. Mishler EG. *The discourse of medicine: Dialectics of medical interviews* New Jersey: Albex
663 Publishing Corporation; 1984.
- 664 33. Thompson-Hodgetts S, Labonte C, Mazumder R, Phelan S. Helpful or harmful? A scoping
665 review of perceptions and outcomes of autism diagnostic disclosure to others. *Research in Autism*
666 *Spectrum Disorders*. 2020; 77: 101596.
- 667 34. Buckman RA. Breaking bad news: The SPIKES strategy. *Community Oncology*. 2005; 2(2): 138-
668 142.

- 669 35. McCluskey L, Casarett D, Siderowf A. Psychosocial adjustment to ALS: a longitudinal study.
670 Amyotroph Lateral Scler Other Motor Neuron Disord. 2004; 5(3): 131-135.
- 671 36. Connolly S, Galvin M, Hardiman O. End-of-life management in patients with amyotrophic lateral
672 sclerosis. *Lancet Neurology*. 2015; 14(4): 435-442.
- 673 37. Shaw JM, Brown RF, Dunn SM. A qualitative study of stress and coping responses in doctors
674 breaking bad news. *Patient Education and Counseling*. 2013; 91(2): 243-248.
- 675 38. Schellenberg KL, Schofield SJ, Fang S, Johnston WS. Breaking bad news in amyotrophic lateral
676 sclerosis: The need for medical education. *Amyotrophic Lateral Sclerosis and Frontotemporal
677 Degeneration*. 2014; 15(1-2): 47-54.
- 678 39. Sparks L, Villagran MM, Parker-Raley J, Cunningham CB. A patient-centered approach to
679 breaking bad news: Communication guidelines for health care providers. *Journal of Applied
680 Communication Research*. 2007; 35(2): 177-198.
- 681 40. O'Brien MR, Whitehead B, Jack BA, Mitchell JD. From symptom onset to a diagnosis of
682 amyotrophic lateral sclerosis/motor neuron disease (ALS/MND): Experiences of people with
683 ALS/MND and family carers—a qualitative study. *Amyotrophic Lateral Sclerosis*. 2011; 12(2): 97-
684 104.
- 685 41. Sisk BA, Bluebond-Langner M, Wiener L, Mack J, Wolfe J. Prognostic Disclosures to Children.
686 *Pediatrics*. 2016a; 138(3): 10.
- 687 42. Sisk B, Frankel R, Kodish E, Harry Isaacson J. The truth about truth-telling in American
688 medicine: A brief history. *The Permanente Journal*. 2016b; 20(3): 74-77.
- 689 43. Marchildon GP. Health systems in transition: Canada: University of Toronto Press; 2013.
- 690 44. Ministry of Health and Long-Term Care. Preventing and managing chronic disease: Ontario's
691 framework. [Online].; 2007. Available from:
692 http://www.health.gov.on.ca/en/pro/programs/cdpm/pdf/framework_full.pdf.
- 693 45. Creswell JW. Qualitative inquiry & research design: Choosing among five approaches. 2nd ed.
694 Thousand Oaks, CA: Sage Publications, Inc.; 2007.
- 695 46. Crabtree BF, L. MW. Doing qualitative research. 2nd ed. Thousand Oaks, CA: Sage Publications,
696 Inc; 1999.
- 697 47. Sofaer S. Qualitative methods: What are they and why use them? *Health Services Research*.
698 1999; 34(5 Pt II): 1101.
- 699 48. Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic
700 lateral sclerosis. *Nature Reviews in Neurology*. 2011; 7(11): 639-349.
- 701 49. Singh S, Wassenaar DR. Contextualising the role of the gatekeeper in social science research.
702 *South African Journal of Bioethics and Law*. 2016; 9(1): 42-46.
- 703 50. Morse JM. Data were saturated. *Qualitative health research*; 25(5): 587-588.
- 704 51. Braun V, Clarke V. Using Thematic Analysis in psychology. *Qualitative Research in Psychology*.
705 2006; 3(2): 77-101.
- 706 52. Charmaz K. Constructionism and the grounded theory method; 2008.
- 707 53. Baxter J, Eyles J. Evaluating qualitative research in social geography: establishing 'rigor' in –
708 qualitative rigor in interview analysis. *Royal Geographical Society*. 1997; 22: 505-525.
- 709 54. Hogden A, Greenfield D, Nugus P, Kiernan MC. What influences patient decision-making in
710 amyotrophic lateral sclerosis multidisciplinary care? A study of patient perspectives. *Patient Prefer
711 Adherence*. 2012b; 6: 829-838.
- 712 55. Chio A, Montuschi A, Cammarosano S, De Mercanti S, Cavallo E, Iardi A, et al. ALS patients
713 and caregivers communication preferences and information seeking behaviour. *European Journal of
714 Neurology*. 2008; 15(1): 55-60.
- 715 56. Daraz L, Morrow AS, Ponce OJ, Beuschel B, Farah MH, Katabi A, et al. Can Patients Trust

- 716 Online Health Information? A Meta-narrative Systematic Review Addressing the Quality of Health
717 Information on the Internet. *Journal of general internal medicine*. 2019; 34(9): 1884-1891.
- 718 57. Abdulla S, Vielhaber S, Machts J, Heinze HJ, Dengler R, Petri S. Information needs and
719 information-seeking preferences of ALS patients and their carers. *Amyotrophic Lateral Sclerosis and*
720 *Frontotemporal Degeneration*. 2014; 15(7-8): 505-512.
- 721 58. Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. Global
722 epidemiology of amyotrophic lateral sclerosis: A systematic review of the published literature.
723 *Neuroepidemiology*. 2013; 41(2): 118-130.
- 724 59. Plage S, Olson RE. Surprise Reveals the Affective-Moral Economies in Cancer Illness
725 Narratives. *Qual Health Res*. 2021; 31(14): 2730-2742.
- 726 60. Marin B, Fontana A, Arcuti S, Copetti M, Boumediene F, Couratier P, et al. Age-specific ALS
727 incidence: A dose-response meta-analysis. *Eur J Epidemiol*. 2018; 33(7): 621-634.